Elevar Therapeutics Shares Results of Phase II Rivoceranib Trial in Patients with Progressive Recurrent or Metastatic Adenoid Cystic Carcinoma

Elevar Therapeutics, Inc. detailed the results of its Phase II clinical trial of rivoceranib, an orally administered tyrosine kinase inhibitor, in patients with progressive recurrent or metastatic adenoid cystic carcinoma.